Culture of Bladder Cancer Organoids as Precision Medicine ToolsPatrick B. Thomas 1,2,3,4, Mahasha P. J. Perera 1,2,3,4,5, Saeid Alinezhad 1,4, Andre Joshi 1,4,5, Paria Saadat 1,2, Clarissa Nicholls 1,2, Caitlin P. Devonport 1,2,4, Alivia R. Calabrese 1,2,3,4, Abby R. Templeton 1,2,3, Jack R. Wood 1,2, Nathan J. Mackenzie 1,2, Penny L. Jeffery 1,2,3,4, Ian Vela *1,2,3,4,5, Elizabeth D. Williams *1,2,3,4
1School of Biomedical Sciences, Faculty of Health, Queensland University of Technology (QUT) at Translational Research Institute, 2Queensland Bladder Cancer Initiative (QBCI), 3Centre for Personalised Analysis of Cancers (CPAC), 4Australian Prostate Cancer Research Centre - Queensland, 5Department of Urology, Princess Alexandra Hospital
Patient-derived organoids (PDOs) are a powerful tool in translational cancer research, reflecting both the genetic and phenotypic heterogeneity of the disease and response to personalized anti-cancer therapies. Here, a consolidated protocol to generate human primary bladder cancer PDOs in preparation for the evaluation of phenotypic analyses and drug responses is detailed.
